Stocks in play: PharmaDrug Inc.

Announced that it has entered into a binding letter of intent, dated January 11, 2021, to acquire Sairiyo Therapeutics Inc. Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration ("FDA") approval. Under the terms of the LOI, PharmaDrug proposes to acquire all of the issued and outstanding shares of Sairiyo in consideration for the issuance of an aggregate of 75,000,000 units of PharmaDrug. Each Unit will be comprised of one common share of PharmaDrug and one common share purchase warrant of PharmaDrug. Each Warrant will entitle the holder thereof to acquire one common share in the capital of PharmaDrug at any time on or before the 18 month anniversary of the issuance of the Warrants at an exercise price of $0.10 per share. Following completion of the transaction Sairiyo will be a wholly-owned subsidiary of the Company. PharmaDrug Inc. shares C.BUZZ are trading up 35.71 percent at $0.10.

Read:

• Psilocybin is Being Studied to Help Treat Autism Spectrum Disorder

• 21st Century Gold: Cryptocurrency Miners Still Accelerating to Record Highs

• This is Why the Psilocybin Story is Quickly Gaining Momentum

• Plant-Based Food Revolution Could Be a $32.29 Billion Investment Opportunity